Details

Autor(en) / Beteiligte

• Mirza, Mansoor R
• Monk, Bradley J
• Herrstedt, Jørn
• Oza, Amit M
• Mahner, Sven
• Redondo, Andrés
• Fabbro, Michel
• Ledermann, Jonathan A
• Lorusso, Domenica
• Vergote, Ignace
• Ben-Baruch, Noa E
• Marth, Christian
• Mądry, Radosław
• Christensen, René D
• Berek, Jonathan S
• Dørum, Anne
• Tinker, Anna V
• du Bois, Andreas
• González-Martín, Antonio
• Follana, Philippe
• Benigno, Benedict
• Rosenberg, Per
• Gilbert, Lucy
• Rimel, Bobbie J
• Buscema, Joseph
• Balser, John P
• Agarwal, Shefali
• Matulonis, Ursula A

Titel

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

Ist Teil von

• The New England journal of medicine, 2016-12, Vol.375 (22), p.2154-2164

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2016

Link zum Volltext

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Among patients with platinum-sensitive, recurrent ovarian cancer, the use of niraparib, a PARP inhibitor, was associated with a significantly longer duration of progression-free survival than placebo, with moderate bone marrow toxicity. Ovarian cancer is a leading cause of death from gynecologic cancers worldwide. 1 , 2 Despite a high initial response rate to platinum and taxane treatment in patients with advanced cancer, the effectiveness of the treatments diminishes over time, and most patients have a relapse. 3 Platinum retreatment is used in patients in whom there is an assumed platinum sensitivity, with diminishing effectiveness and a cumulative increase in toxicity. 3 Niraparib is a highly selective inhibitor of poly(adenosine diphosphate [ADP]–ribose) polymerase (PARP) 1/2, 4 nuclear proteins that detect DNA damage and promote its repair. Clinical studies have evaluated PARP inhibitors in patients with recurrent ovarian . . .